The board of directors of TRANSTHERA-B (02617) has announced the appointment of Mr. Sun Delong as the company's Chief Operating Officer, effective from June 12, 2026.

In this role, Mr. Sun will be responsible for overseeing all aspects of the company's commercial operations. He brings over twenty years of extensive experience in the biopharmaceutical industry, with comprehensive management capabilities spanning from frontline pharmaceutical marketing and academic promotion to overall enterprise operations.